MHRA Drug Safety Update July 2019

MHRA Drug Safety Update July 2019

July 18, 2019

Date issued: 17th July 2019

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 12 July 2019) has been published and includes articles on:

  • Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
  • Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation
  • Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food
  • Letters and drug alerts sent to healthcare professionals in June 2019
  • Medical Device Alerts issued in June 2019

To see the latest MHRA Drug Safety Update in full, visit the GOV.uk website.



Posted in:


More Latest News >

Metformin Safety Update

The Medicines and Healthcare products Regulatory Agency (MHRA) has been made aware that outside of the UK very low amounts...

PQS: NSAID quality criterion

This news story highlights several points on the non-steroidal anti-inflammatory drug (NSAID) quality criterion of the Pharmacy Quality Scheme (PQS)...